TY - JOUR AU - Akhabue, Ehimare AU - Synnestvedt, Marie AU - Weiner, Mark G. AU - Bilker, Warren B. AU - Lautenbach, Ebbing T1 - Cefepime-Resistant Pseudomonas aeruginosa T2 - Emerging Infectious Disease journal PY - 2011 VL - 17 IS - 6 SP - 1037 SN - 1080-6059 AB - Resistance to extended-spectrum cephalosporins complicates treatment of Pseudomonas aeruginosa infections. To elucidate risk factors for cefepime-resistant P. aeruginosa and determine its association with patient death, we conducted a case–control study in Philadelphia, Pennsylvania. Among 2,529 patients hospitalized during 2001–2006, a total of 213 (8.4%) had cefepime-resistant P. aeruginosa infection. Independent risk factors were prior use of an extended-spectrum cephalosphorin (p<0.001), prior use of an extended-spectrum penicillin (p = 0.005), prior use of a quinolone (p<0.001), and transfer from an outside facility (p = 0.01). Among those hospitalized at least 30 days, mortality rates were higher for those with cefepime-resistant than with cefepime-susceptible P. aeruginosa infection (20.2% vs. 13.2%, p = 0.007). Cefepime-resistant P. aeruginosa was an independent risk factor for death only for patients for whom it could be isolated from blood (p = 0.001). Strategies to counter its emergence should focus on optimizing use of antipseudomonal drugs. 1Current affiliation: Duke University School of Medicine, Durham, North Carolina, USA. KW - resistance KW - cefepime KW - Pseudomonas aeruginosa KW - risk factors KW - outcomes KW - bacteria KW - research KW - United States DO - 10.3201/eid1706.100358 UR - https://wwwnc.cdc.gov/eid/article/17/6/10-0358_article ER - End of Reference